PBS reports President Trump tapped White House health aide Dr. Heidi Overton to lead the FDA

The announcement would move a senior Trump health-policy figure to the Food and Drug Administration, at a time when the agency is also processing multiple regulatory petitions published in the Federal Register. PBS said Overton has supported the administration’s health agenda, including changes to the childhood vaccine schedule that drew criticism from some medical experts.

3 min readEditor-approved Apex article

President Donald Trump has tapped Dr. Heidi Overton, described by PBS NewsHour Politics as one of his top White House health policy aides, to lead the Food and Drug Administration, according to PBS. As of publication, PBS’s report was the primary published account of the selection, and this report could not be independently confirmed through a White House personnel announcement or a Federal Register notice in the materials reviewed for this package.

PBS said Overton has been a strong supporter of the president’s health agenda while serving in the White House. The network also pointed to Overton’s involvement in efforts to overhaul the childhood vaccine schedule, and said that those changes have drawn sharp criticism from medical experts.

If the selection proceeds through the required FDA leadership process, the practical effect would be to place a White House health-policy adviser in charge of an agency that regulates prescription and over-the-counter drugs, vaccines, medical devices, and significant portions of the nation’s food-safety and color-additive regulatory framework. FDA also publishes Federal Register notices for specific petitions and rulemaking actions, including requests to update permitted uses of certain ingredients in foods.

Overton’s anticipated role at FDA would come as the agency continues to manage ongoing regulatory submissions. On August 19, 2026, the Federal Register posted FDA notices announcing it had received multiple color-additive petitions, including filings related to proposed changes to regulations for products such as acetone used as a solvent in the manufacture of carrot oil, safflower extract as a color additive, and genipin blue for food uses. Those notices reflect the agency’s continued administrative workload regardless of leadership changes.

Public debate around pediatric vaccination schedules has often included questions about schedule timing, evidence thresholds, and how policy changes are communicated to clinicians and families. PBS’s report said the childhood-vaccine efforts associated with Overton have faced criticism from medical experts, underscoring that any FDA leadership role would likely bring the issue into sharper focus for stakeholders watching future FDA actions, guidance, and communications.

A leadership change at FDA also typically has legal and institutional implications for how the agency coordinates with other federal health bodies and carries out rulemaking. FDA actions can include proposed and final regulations, agency guidance, and review timelines for applications, all of which depend on the agency’s leadership priorities and internal management decisions.

Next steps would depend on the formal administrative record for the nomination or appointment, including whether and when the White House provides an official personnel announcement and whether any Federal Register or other official notice addresses the appointment. PBS’s report was presented as a matter of who will lead the agency, but the materials reviewed here do not include the official appointing document.

keyFacts were limited to what could be supported by the reviewed reporting, and additional confirmation is needed before stating the appointment as an official fact. If official documentation is found, this story would be updated to include the date of the announcement, the legal authority used, and any Senate confirmation or other procedural requirements relevant to the FDA post.

Why It Matters

FDA leadership affects how the agency prioritizes and administers major regulatory areas, including vaccines, drugs, devices, and food-related ingredient regulations.
If Overton is confirmed or appointed, the childhood vaccine schedule issue referenced by PBS would likely remain a high-visibility policy area requiring FDA coordination and stakeholder engagement.
Federal Register notices show FDA continues processing ingredient and regulatory petitions while leadership transitions are pending.
The absence of an official personnel record in the reviewed materials means legal status and procedural steps (including any confirmation requirements) should be treated as unresolved until official documentation is located.

Sources

Key Facts

PBS NewsHour Politics reported that President Donald Trump has tapped Dr. Heidi Overton to lead the Food and Drug Administration.
PBS described Overton as a top White House health policy aide and said she has supported the administration’s health agenda.
PBS said Overton has supported efforts to overhaul the childhood vaccine schedule, a move PBS said has drawn sharp criticism from medical experts.
As of the materials reviewed for this package, an official White House or Federal Register confirmation of the FDA leadership selection was not found.
The Federal Register posted FDA announcements on August 19, 2026, including multiple color-additive petition filings unrelated to the leadership change.